The Role of CHMP4C on Proliferation in the Human Lung Cancer A549 Cells

Kang Li, Jianxiang Liu, Mei Tian, Chunnan Piao, Jianlei Ruan, Ling Gao, Xuesong Qi, Gang Gao, Xu Su^*

Key Laboratory of Radiological Protection and Nuclear Emergency, China CDC, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing, China.

DOI: 10.4236/jct.2015.615133                

Abstract

The human lung cancer has high incidence rate and mortality among the carcinoma. The research on enhancing the efficacy of therapy for lung cancer is significant. A resent research found that as a subunit of ESCRT-III, CHMP4C functioned to retard abscission timing to coordinate midbody resolution and prevent accumulation of DNA damage in the abscission checkpoint through phosphorylated by AuroraB. In the current study, we evaluated the possible mechanism of the effects of CHMP4C inhibition on cell cycle and cell survival in A549 cells. We found that CHMP4C knockdown caused lagging S phase in cell cycle through enhancing the phosphorylation of Rb, raising the expression of cyclin B1-cdc2 and suppressing the activation of cyclin A. Meanwhile, CHMP4Cdeletion depressed cell survival via decreasing cell viability and increasing caspase 3/7 activity. This study may promote new significant reference and advance for the mechanism underlying specific function of CHMP4C as well as further research on enhancing therapy effect on non-small lung cancer.

Keywords

The Human Lung Cancer, A549, CHMP4C, siRNA

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Nguyen, K.S., Neal, J.W. and Wakelee, H. (2014) Review of the Current Targeted Therapies for Non-Small-Cell Lung Cancer. World Journal of Clinical Oncology, 5, 576-587. http://dx.doi.org/10.5306/wjco.v5.i4.576
[2]	Liu, Y.-T., Hao, X.-Z., Li, J.-L., Hu, X.-S., Wang, Y., Wang, Z.-P. and Shi, Y.-K. (2015) Survival of Patients with Advanced Lung Adenocarcinoma before and after Approved Use of Gefitinib in China. Thoracic Cancer, 6, 636-642. http://dx.doi.org/10.1111/1759-7714.12267
[3]	Carlton, J.G., Caballe, A., Agromayor, M., Kloc, M. and Martin-Serrano, J. (2012) ESCRT-III Governs the Aurora B-Mediated Abscission Checkpoint through CHMP4C. Science, 336, 220-225. http://dx.doi.org/10.1126/science.1217180
[4]	Jimenez, A.J., Maiuri, P., Lafaurie-Janvore, J., Divoux, S., Piel, M. and Perez, F. (2014) ESCRT Machinery Is Required for Plasma Membrane Repair. Science, 343, 1247136. http://dx.doi.org/10.1126/science.1247136
[5]	Lafaurie-Janvore, J., Maiuri, P., Wang, I., Pinot, M., Manneville, J.-B., Betz, T. and Piel, M. (2013) ESCRT-III Assembly and Cytokinetic Abscission Are Induced by Tension Release in the Intercellular Bridge. Science, 339, 1625-1629. http://dx.doi.org/10.1126/science.1233866
[6]	Pharoah, P.D.P., Tsai, Y.-Y., Ramus, S.J., Phelan, C.M., Goode, E.L., Lawrenson, K. and Sellers, T.A. (2013) GWAS Meta-Analysis and Replication Identifies Three New Susceptibility Loci for Ovarian Cancer. Nature Genetics, 4, 362-370. http://dx.doi.org/10.1038/ng.2564
[7]	van der Waal, M.S., Hengeveld, R.C.C., van der Horst, A. and Lens, S.M.A. (2012) Cell Division Control by the Chromosomal Passenger Complex. Experimental Cell Research, 318, 1407-1420. http://dx.doi.org/10.1016/j.yexcr.2012.03.015
[8]	Feng, Z. (2010) p53 Regulation of the IGF-1/AKT/mTOR Pathways and the Endosomal Compartment. Cold Spring Harbor Perspectives in Biology, 2, a001057. http://dx.doi.org/10.1101/cshperspect.a001057
[9]	Lim, S. and Kaldis, P. (2013) Cdks, Cyclins and CKIs: Roles Beyond Cell Cycle Regulation. Development, 140, 3079-3093. http://dx.doi.org/10.1242/dev.091744
[10]	Liu, P., Slater, D.M., Lenburg, M., Nevis, K., Cook, J.G. and Vaziri, C. (2009) Replication Licensing Promotes Cyclin D1 Expression and G(1) Progression in Untransformed Human Cells. Cell Cycle (Georgetown, Tex), 8, 125-136. http://dx.doi.org/10.4161/cc.8.1.7528
[11]	Gower, A., Wang, Y. and Giaccone, G. (2014) Oncogenic Drivers, Targeted Therapies, and Acquired Resistance in Non-Small-Cell Lung Cancer. Journal of Molecular Medicine (Berlin), 92, 697-707. http://dx.doi.org/10.1007/s00109-014-1165-y
[12]	Yu, X., Riley, T. and Levine, A.J. (2009) The Regulation of the Endosomal Compartment by p53 the Tumor Suppressor Gene. FEBS Journal, 276, 2201-2212. http://dx.doi.org/10.1111/j.1742-4658.2009.06949.x
[13]	Walsh, J.G., Cullen, S.P., Sheridan, C., Lüthi, A.U., Gerner, C. and Martin, S.J. (2008) Executioner Caspase-3 and Caspase-7 Are Functionally Distinct Proteases. Proceedings of the National Academy of Sciences of the United States of America, 105, 12815-12819. http://dx.doi.org/10.1073/pnas.0707715105
[14]	Yoon, I., Chung, J., Hahm, S., Park, M., Lee, Y., Ko, S. and Han, Y. (2011) Ribosomal Protein S3 Is Phosphorylated by Cdk1/cdc2 during G2/M Phase. BMB Reports, 44, 529-534. http://dx.doi.org/10.5483/BMBRep.2011.44.8.529
[15]	Tsuchiya, Y., Murai, S. and Yamashita, S. (2015) Dual Inhibition of Cdc2 Protein Kinase Activation during Apoptosis in Xenopus Egg Extracts. FEBS Journal, 282, 1256-1270. http://dx.doi.org/10.1111/febs.13217
[16]	Lee, M., Cho, Y., Jung, B., Kim, S., Kang, Y., Pan, C. and Kim, Y. (2015) Parkin Induces G2/M Cell Cycle Arrest in TNF-α-Treated HeLa Cells. Biochem. Biochemical and Biophysical Research Communications, 464, 63-69. http://dx.doi.org/10.1016/j.bbrc.2015.05.101
[17]	Lapenna, S. and Giordano, A. (2009) Cell Cycle Kinases as Therapeutic Targets for Cancer. Nature Reviews Drug Discovery, 8, 547-566. http://dx.doi.org/10.1038/nrd2907